Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT06176768
- Locations
- 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
A Relative Bioavailability Study of LY3454738 in Healthy Participants
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06173895
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06169982
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06165146
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A First-In-Human Study of LY3839840 in Healthy Participants
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT06153355
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸CenExel ACT, Anaheim, California, United States
A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 225
- Registration Number
- NCT06148272
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore
🇺🇸CenExel ACT, Anaheim, California, United States
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1040
- Registration Number
- NCT06143956
- Locations
- 🇺🇸
Pacific Diabetes & Endocrine Center, Honolulu, Hawaii, United States
🇺🇸Medical Research Partners, Ammon, Idaho, United States
🇺🇸Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT06132126
- Locations
- 🇺🇸
Labcorp CRU, Dallas, Texas, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
🇺🇸CenExel ACT, Anaheim, California, United States
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT06124807
- Locations
- 🇺🇸
Central Washington Health Services Association d/b/a Confluence Health, Wenatchee, Washington, United States
🇺🇸The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1016
- Registration Number
- NCT06119581
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇦🇹Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria